Advancing precision medicine with molecular glues

Magnet Biomedicine’s modular TrueGlue™ technology enables the systematic discovery of molecular glues toward the treatment of human disease.

Graphic Shape
Graphic Shape
Graphic line Shape
Magnet Biomedicine scientist in the lab pipetting.

The Science

TrueGlues are small molecules that localize drug effects to disease-relevant targets in complex with tissue-enriched “presenter” proteins.

Magnet is advancing precision medicine through the rational selection of protein pairs and systematic design of monovalent molecular glues. Combining the benefits of small molecule drugs with the advantages conferred by cooperative interactions with a presenter protein, TrueGlues offer the potential to address the most challenging targets in a tissue-localized manner.

3D schema outlining the mechanism by which TrueGlues engage with presenter proteins and disease targets.

Since their discovery more than three decades ago, molecular glues have demonstrated vast potential to treat human disease.

Recent advancements in the field have largely focused on targeted protein degradation, leaving the expansive potential of molecular glues untapped. Magnet is reimagining what’s possible with molecular glues by venturing beyond known protein-protein interactions (PPIs) and analyzing the broad protein landscape to pair target proteins with endogenous presenter proteins for maximum therapeutic impact.

Uniquely enabled by its platform capabilities, Magnet is pioneering the discovery of novel molecular glue medicines to address a range of indications with high unmet need, including cancer, immune disorders, and cardiovascular disease.

Rationally designed TrueGlues localize drug effects to disease-relevant tissues, providing unique opportunities to maximize the therapeutic index by minimizing on-target-off-tissue toxicity.

TrueGlues offer opportunities to induce biological synergy, target historically undruggable proteins, and alter protein localization to enable mechanisms of action that are not attainable by traditional small molecule inhibitors.

OUR TECHNOLOGY

Building upon recent advances in proteomics, screening, and bioinformatics, we believe the time is now to execute on this long-standing goal of rational molecular glue discovery.

Our TrueGlue discovery platform combines state-of-the-art screening technologies utilizing diverse chemical libraries and human biology–driven target and presenter selection. Our process integrates diverse streams of in-house and external data to discover and exploit novel molecular glue mechanisms of action.  Magnet’s TrueGlue technology can be applied in an indication-agnostic manner to discover molecular glues with a wide range of target modulation, drug-like properties, and selectivity.

Scientific illustration depicting how TrueGlues enable tissue-specific target inhibition to minimize toxicity.
TrueGlues enable tissue-specific target inhibition to minimize toxicity.
Graphic Shape
Graphic Shape
Graphic line Shape

OUR PEOPLE

Magnet’s team combines decades of drug‑discovery experience and an innovative TrueGlue pipeline.

Our diverse scientific expertise has enabled a multipronged approach that pushes the boundaries of existing technology to advance TrueGlues as a new therapeutic modality with the potential to alter the treatment landscape in cancer, autoimmune, and cardiovascular diseases.

Magnet Biomedicine scientist in a lab pipetting into a conical centrifuge tube.
Brian Safina Headshot

Brian Safina, PhD

President & Chief Executive Officer
bret williams headshot

Bret Williams, PhD

Senior Vice President of Research
matthew-hayward-headshot

Matthew Hayward, PhD

Vice President of Drug Discovery
jennifer-franklin-headshot

Jennifer Franklin

Vice President of Operations
kristina-burow-headshot

Kristina Burow

Managing Director at ARCH Venture Partners
Thomas Cahill headshot

Thomas Cahill, MD, PhD

Founder and Managing Partner at Newpath Partners
ramnik-xavier-headshot

Ramnik Xavier, MD, PhD

Scientific Advisory Board Chair
Benjamin F. Cravatt headshot

Benjamin F. Cravatt, PhD

Founder & Advisor
David A. Spiegel headshot

David A. Spiegel, MD, PhD

Founder & Advisor
Michael Rosbash

Michael Rosbash, PhD

Founder & Advisor
 Richa Saxena headshot

Richa Saxena, PhD

Founder & Advisor
Stuart Schreiber headshot

Stuart Schreiber, PhD

Founder & Advisor
Joshua Alper Headshot

Joshua Alper, PhD

Biomolecular Discovery
Chelsea Ankeny headshot

Chelsea Ankeny

Office Manager
Austin Carr headshot

Austin Carr, PhD

Proteomics
Xiao Chen headshot

Xiao Chen, PhD

Biology
YiQun Chen headshot

YiQun Chen

Biology
Jessica Gasser headshot

Jessica Gasser, PhD

Biology
Shubhroz Gill headshot

Shubhroz Gill, PhD

Biology
Adarsh Godbole Headshot

Adarsh Godbole

Protein Production
Yuan Hu Headshot

Yuan Hu, PhD

Computational Chemistry
Bruce Hua headshot

Bruce Hua, PhD

Chemistry
Liam Hudson headshot

Liam Hudson, PhD

Chemistry
Anita Kim headshot

Anita Kim

Lab Operations
Chueh-Ling Kuo headshot

Chueh-Ling Kuo, PhD

Biomolecular Discovery
Jason Lowe headshot

Jason Lowe, PhD

Chemistry
Alyssa Lutservitz headshot

Alyssa Lutservitz, MS

Informatics
Ashish Maurya headshot

Ashish Maurya, PhD

Biology
Jessica McManus Headshot

Jessica McManus

Biology
Francesca Pisanzio headshot

Francesca Pisanzio

Biology
James Ralff headshot

James Ralff

Compound Management
Andrew Reidenbach headshot

Andrew Reidenbach, PhD

Biomolecular Discovery
David Rhee headshot

David Rhee, PhD

Proteomics
Anthony Scruse Headshot

Anthony Scruse, PhD

Chemistry
Luke Stamatakis headshot

Luke Stamatakis, CPA

Finance & Accounting
Tom Tian headshot

Tom Tian, PhD

Biology
Tiffany Tsang headshot

Tiffany Tsang, PhD

Biology
Go Watanabe headshot

Go Watanabe, PhD

Protein Production
Teruki Watanabe Headshot

Teruki Watanabe, PhD

Chemistry
Lauren Weiss Headshot

Lauren Weiss

Biology
Hsin-Lan Wen headshot

Hsin-Lan Wen, PhD

Biology
Graphic line Shape
Graphic Blob Shape

CAREERS

Magnet Biomedicine is building a world-class team to unleash the scientific breakthroughs and expertise of our founders.

We are looking for creative, thoughtful, science-first innovators to join our collaborative team. Come help us realize the potential of molecular glues to achieve the broadest possible impact for patients.

Sr. RA/Associate Scientist; Biophysics/Biochemistry

Graphic line Shape
Graphic Shape

News

The latest Magnet news and presentations

09.20.2023

Magnet Biomedicine Emerges from Stealth with $50 Million to Advance Rational Approach to Molecular Glues with TrueGlue™ Discovery Platform